Literature DB >> 7865988

Treatment of acute gouty arthritis with the 5-hydroxytryptamine antagonist ondansetron.

H Schwörer1, G Ramadori.   

Abstract

We report on a 28-year-old man with hematemesis, renal dysfunction, and arterial hypertension who suffered from an acute gouty attack presenting as podagra. Because of the accompanying symptoms conventional treatment of the gouty attack with colchicine or nonsteroidal anti-inflammatory drugs was contraindicated. We treated the pain of acute arthritis with the specific 5-hydroxytryptamine subtype 3 receptor antagonist ondansetron. Within 30 min after intravenous injection of this drug a substantial degree of pain relief had occurred. Unwanted side effects due to treatment were not observed. It is suggested that the 5-hydroxytryptamine released during a gouty attack induces pain via activation of 5-hydroxytryptamine subtype 3 receptors on nociceptive afferent nerve fibers. 5-Hydroxytryptamine subtype 3 receptor antagonists may therefore be a novel class of drugs for the effective treatment of acute gouty attacks when conventional treatment is contraindicated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865988     DOI: 10.1007/bf00180553

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  11 in total

1.  The contribution of neurogenic inflammation in experimental arthritis.

Authors:  J D Levine; M A Moskowitz; A I Basbaum
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

2.  Influence of a specific 5-HT3 antagonist on carrageenan-induced hyperalgesia in rats.

Authors:  A Eschalier; V Kayser; G Guilbaud
Journal:  Pain       Date:  1989-02       Impact factor: 6.961

Review 3.  Arthritis and the nervous system.

Authors:  M Fitzgerald
Journal:  Trends Neurosci       Date:  1989-03       Impact factor: 13.837

Review 4.  Mediators of crystal-induced inflammation in the joint.

Authors:  A D Woolf; P A Dieppe
Journal:  Br Med Bull       Date:  1987-04       Impact factor: 4.291

Review 5.  Mediators of vasodilatation in the skin.

Authors:  F Lembeck
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

6.  Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

Authors:  B P Richardson; G Engel; P Donatsch; P A Stadler
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

7.  Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats.

Authors:  J Giordano; L V Rogers
Journal:  Eur J Pharmacol       Date:  1989-10-24       Impact factor: 4.432

Review 8.  Prevention and management of gout.

Authors:  V L Star; M C Hochberg
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 9.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony Markham; Eugene M Sorkin
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse.

Authors:  J Giordano; J Dyche
Journal:  Neuropharmacology       Date:  1989-04       Impact factor: 5.250

View more
  1 in total

Review 1.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.